Show simple item record

COVID-19 in teriflunomide-treated patients with multiple sclerosis

dc.contributor.authorMaghzi, Amir Hadi
dc.contributor.authorHoutchens, Maria K.
dc.contributor.authorPreziosa, Paolo
dc.contributor.authorIonete, Carolina
dc.contributor.authorBeretich, Biljana D.
dc.contributor.authorStankiewicz, James M.
dc.contributor.authorTauhid, Shahamat
dc.contributor.authorCabot, Ann
dc.contributor.authorBerrios Morales, Idanis
dc.contributor.authorSchwartz, Tamara H. W.
dc.contributor.authorSloane, Jacob A.
dc.contributor.authorFreedman, Mark S.
dc.contributor.authorFilippi, Massimo
dc.contributor.authorWeiner, Howard L.
dc.contributor.authorBakshi, Rohit
dc.date2022-08-11T08:08:11.000
dc.date.accessioned2022-08-23T15:45:49Z
dc.date.available2022-08-23T15:45:49Z
dc.date.issued2020-06-03
dc.date.submitted2020-07-08
dc.identifier.citation<p>Maghzi AH, Houtchens MK, Preziosa P, Ionete C, Beretich BD, Stankiewicz JM, Tauhid S, Cabot A, Berriosmorales I, Schwartz THW, Sloane JA, Freedman MS, Filippi M, Weiner HL, Bakshi R. COVID-19 in teriflunomide-treated patients with multiple sclerosis. J Neurol. 2020 Jun 3:1–7. doi: 10.1007/s00415-020-09944-8. Epub ahead of print. PMID: 32494856; PMCID: PMC7268971. <a href="https://doi.org/10.1007/s00415-020-09944-8">Link to article on publisher's site</a></p>
dc.identifier.issn0340-5354 (Linking)
dc.identifier.doi10.1007/s00415-020-09944-8
dc.identifier.pmid32494856
dc.identifier.urihttp://hdl.handle.net/20.500.14038/27616
dc.description.abstractThe outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.
dc.language.isoen_US
dc.relation<p><a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=pubmed&cmd=Retrieve&list_uids=32494856&dopt=Abstract">Link to Article in PubMed</a></p>
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7268971/
dc.subjectAntiviral
dc.subjectCOVID-19
dc.subjectCoronavirus
dc.subjectMultiple sclerosis
dc.subjectTeriflunomide
dc.subjectHealth Services Administration
dc.subjectImmune System Diseases
dc.subjectImmunotherapy
dc.subjectInfectious Disease
dc.subjectNervous System Diseases
dc.subjectVirus Diseases
dc.titleCOVID-19 in teriflunomide-treated patients with multiple sclerosis
dc.typeJournal Article
dc.source.journaltitleJournal of neurology
dc.identifier.legacycoverpagehttps://escholarship.umassmed.edu/covid19/67
dc.identifier.contextkey18421080
html.description.abstract<p>The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.</p>
dc.identifier.submissionpathcovid19/67
dc.contributor.departmentDepartment of Neurology


This item appears in the following Collection(s)

Show simple item record